Welcome to our dedicated page for Hutchmed (China) news (Ticker: HCM), a resource for investors and traders seeking the latest updates and insights on Hutchmed (China) stock.
HUTCHMED (China) Limited develops and commercializes targeted therapies and immunotherapies for cancer and immunological diseases through a China-based commercial organization and a global clinical pipeline. News for HCM centers on marketed oncology products such as FRUZAQLA and ELUNATE for fruquintinib, ORPATHYS for savolitinib, China regulatory actions, and partner-driven commercialization outside China.
Recurring updates also cover pipeline compounds including sovleplenib, HMPL-760 and HMPL-A580, clinical data presented at oncology meetings, and the company’s Antibody-Targeted Therapy Conjugate platform. Corporate items include annual results, product-license updates such as TAZVERIK in China, board and committee changes, and disclosures tied to HUTCHMED’s Nasdaq, AIM and HKEX listings and ADR structure.
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) announced that the NDA for sovleplenib in adult warm antibody autoimmune hemolytic anemia (wAIHA) was accepted for review by the NMPA with Priority Review and Breakthrough Therapy Designation.
The submission is supported by ESLIM-02 Phase II/III data: the Phase III part met its primary durable hemoglobin response endpoint in January 2026; Phase II published in The Lancet Haematology showed ORR 43.8% vs 0% at eight weeks and 66.7% over 24 weeks. ClinicalTrials.gov ID: NCT05535933.
HUTCHMED (NASDAQ/AIM:HCM; HKEX:13) will present new preclinical and clinical data at the AACR Annual Meeting 2026 (April 17-22, 2026) in San Diego.
Key highlights include preclinical data for HMPL-A580—an EGFR-targeted ATTC with a PI3K/PIKK inhibitor payload showing IC50 ~1–10 nM, dose‑dependent antitumor activity at 1–10 mg/kg in mouse xenografts, plasma stability across species, and favorable PK in cynomolgus monkeys. Updated investigator‑initiated Phase Ib/II and exploratory Phase II surufatinib combination studies in small bowel, appendiceal, and pancreatic cancers will also be presented.
HUTCHMED (Nasdaq/AIM: HCM) initiated a registrational Phase III trial of HMPL-760 plus R-GemOx in relapsed/refractory diffuse large B-cell lymphoma in China; first patient dosed on March 20, 2026.
The randomized, double-blind study (NCT07409428) plans to enroll ~240 patients, with primary endpoints of investigator-assessed PFS and OS, and secondary measures including ORR, CRR, DoR, safety and PK.
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) reports that Ipsen is withdrawing TAZVERIK (tazemetostat) worldwide after SYMPHONY-1 safety findings. HUTCHMED Limited has suspended sales/shipments, initiated recalls across mainland China, Hong Kong and Macau, and stopped active tazemetostat trials; patient care and regulator notifications are underway.
2025 sales of TAZVERIK were US$2.5 million. The company says the withdrawal is not expected to affect its financial guidance.
HUTCHMED (Nasdaq/AIM: HCM, HKEX: 13) announced that Professor Mok Shu Kam, Tony will retire and not seek re-election at the AGM on May 12, 2026, ceasing his role as Independent Non-executive Director and as chair/member of board committees due to nearing the nine-year tenure cap under Hong Kong Listing Rules.
Effective at the conclusion of the AGM and subject to re-election of directors, the Board approved committee changes: Dr Renu Bhatia appointed Senior and Lead Independent Non-executive Director and Nomination Committee chair; Dr Chaohong Hu appointed Technical Committee chair; and Professor Tan Shao Weng, Daniel joined the Sustainability Committee.
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) reported 2025 results with net income attributable of $456.9 million and a year-end cash balance of $1.4 billion, driven largely by a $415.8 million post-tax divestment gain. Total in-market sales reached $524.7 million (+5%), led by FRUZAQLA® sales of $366.2 million (+26%). Consolidated revenue was $548.5 million (-13%) as oncology consolidated revenue declined to $214.4 million (-21%).
The company advanced its ATTC platform, dosing first patient for HMPL-A251 in December 2025 and initiating further ATTC trials in 2026, while multiple late-stage programs and regulatory filings progressed.
HUTCHMED (Nasdaq/AIM:HCM) initiated a first-in-human Phase I/IIa trial of HMPL-A580 on March 4, 2026. HMPL-A580 is the company’s second Antibody-Targeted Therapy Conjugate (ATTC), combining a PI3K/PIKK inhibitor payload with an anti-EGFR antibody.
The multicenter, open-label study in China and the US will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with a Phase I dose-escalation to find the maximum tolerated dose and a Phase IIa expansion to further characterize activity. ClinicalTrials.gov identifier NCT07396584.
HUTCHMED (Nasdaq/AIM: HCM; SEHK:13) will announce its final results for the year ended December 31, 2025 on Thursday, March 5, 2026.
Management will host two webcast presentations for analysts and investors with Q&A. The English webcast is at 8:00 am EST and the Chinese (Putonghua) webcast at 8:30 am HKT. Slides and replays will be available via the company website.
HUTCHMED (Nasdaq/AIM: HCM) highlighted that results from the randomized Phase III SACHI trial were published in The Lancet on Jan 14, 2026, confirming efficacy of MET inhibition in advanced EGFR‑mutant NSCLC with acquired MET amplification after progression on prior EGFR‑TKI therapy.
The trial evaluated the oral combination of savolitinib (ORPATHYS) plus osimertinib (TAGRISSO). Based on interim SACHI data, the savolitinib+osimertinib combination received regulatory approval in China in June 2025. The program is jointly developed by AstraZeneca and HUTCHMED.
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) announced that the Phase III registration part of the ESLIM-02 trial of sovleplenib, a Syk inhibitor for adult warm antibody autoimmune hemolytic anemia (wAIHA) in China, met its primary endpoint of durable hemoglobin response during weeks 5–24.
The randomized, double‑blind, placebo‑controlled study enrolled patients with primary or secondary wAIHA who relapsed or were refractory to ≥1 prior standard therapy. Earlier Phase II data reported overall response 43.8% vs 0% at 8 weeks and 66.7% at 24 weeks for sovleplenib with a favourable safety profile. HUTCHMED plans to submit a NDA to NMPA in H1 2026. Full ESLIM-02 results will be presented at an upcoming scientific conference.